CST and AstraZeneca collaborate on PhosphoScan Platform
CST’s PhosphoScan proteomics technology is a patented methodology that enables the discovery of drug target phospho-profiles (PhosphoSignatures) in cells and disease tissues. In the current research project, PhosphoScan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.